Back to User profile » Professor Xiaorui Fu
Papers published by Professor Xiaorui Fu:
Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases
Du L, Zhang L, Li L, Li X, Yan J, Wang X, Fu X, Sun Z, Zhang X, Li Z, Wu J, Yu H, Chang Y, Zhou Z, Nan F, Wu X, Tian L, Zhang M
OncoTargets and Therapy 2020, 13:7189-7197
Published Date: 27 July 2020
Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
Ma X, Li L, Zhang L, Fu X, Li X, Wang X, Wu J, Sun Z, Zhang X, Feng X, Chang Y, Zhou Z, Nan F, Zhang J, Li Z, Zhang M
Drug Design, Development and Therapy 2020, 14:275-284
Published Date: 22 January 2020
Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
Zhang F, Li L, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Kong F, Ren L, Zhang M
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:33-43
Published Date: 19 August 2019
Clinical features and prognostic factors of primary bone marrow lymphoma
Wang G, Chang Y, Wu X, Li X, Li L, Zhang L, Fu X, Sun Z, Zhang X, Zhang M
Cancer Management and Research 2019, 11:2553-2563
Published Date: 29 March 2019
Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study
Ma Q, Chang Y, Li L, Li X, Wang X, Wu J, Fu X, Sun Z, Yu H, Zhang X, Zhou Z, Nan F, Li Z, Liu X, Zhao Q, Li Y, Zhang L, Zhang M, Zhang L
Cancer Management and Research 2019, 11:1363-1372
Published Date: 11 February 2019